CD40 ligand level – vascular inflammation activity and long6term prognosis in coronary heart disease patients
Abstract
Aim. To study prognostic value of plasma soluble CD40 ligand (sCD40L) level in patients with various coronary heart disease (CHD) forms.
Material and methods. In total, 65 CHD patients were examined, including 26 with stable effort angina (SEA), functional class (FC) I6III; 23 – with unstable angina (UA), Stage II6IIIB; 15 – with myocardial infarction (MI). Levels of sCD40L, highly sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), and fibrinogen were measured. Follow-up period lasted for 24 months. End-points included death from any cause, non6fatal MI, ischemic stroke, myocardial revascularization, hospitalization due to SEA progression or UA development.
Results. In SEA, UA and MI patients, sCD40L levels were similar. Type 2 diabetes mellitus (DM-2) patients had significantly higher sCD40L levels, comparing to other CHD participants. Cardiovascular event (CVE)-free survival analysis demonstrated that in CHD patients with low sCD40L levels, survival was significantly better than in participants with its higher levels, even after DM-2 patients' exclusion.
Conclusion. In CHD patients, initially increased sCD40L level is an independent predictor of adverse CVE during two-year follow-up.
About the Authors
O. P. ShevchenkoRussian Federation
O. F. Prirodova
Russian Federation
A. O. Shevchenko
Russian Federation
O. V. Orlova
Russian Federation
A. N. Britov
Russian Federation
References
1. Aukrust P, Mu?ller F, Ueland T, et al. Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina. Circulation 1999; 100: 614–20.
2. Cipollone F, Mezzetti A, Porreca E, et al. Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia Effects of Statin Therapy. Circulation 2002; 106: 399–402.
3. Freedman JE. CD406CD40L and Platelet Function Beyond Hemostasis. Circ Res 2003; 92: 944–6.
4. Garlichs CD, Eskafi S, Raaz D, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86: 649–55.
5. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 Ligand in Acute Coronary Syndromes. N Engl J Med 2003; 348: 1104–11.
6. Inwald DP, McDowall A, Peters MJ, et al. CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation. Circ Res 2003; 92: 1041–8.
7. Kinlay SS, Schwartz GG, Olsson AG, et al. Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL]. Circulation 2004; 110: 386–91.
8. Locksley R, Killeen N, Lenardo M. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501.
9. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931–6.
10. Marx N, Imhof A, Froehlich J, et al. Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease. Circulation 2003; 107: 1954–7.
11. Schonbeck U, Libby P. CD40 Signaling and Plaque Instability. Circ Res 2001; 89: 1092–103.
12. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L Risk Prediction After Acute Coronary Syndromes. Circulation 2003; 108: 1049–52.
Review
For citations:
Shevchenko O.P., Prirodova O.F., Shevchenko A.O., Orlova O.V., Britov A.N. CD40 ligand level – vascular inflammation activity and long6term prognosis in coronary heart disease patients. Cardiovascular Therapy and Prevention. 2008;7(1):39-45.
Email this article 
